These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8579978)

  • 1. Treatment of scleroderma.
    Gelber AC; Wigley FM
    Curr Opin Rheumatol; 1995 Nov; 7(6):551-9. PubMed ID: 8579978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and treatment of scleroderma.
    Adnan ZA
    Acta Med Indones; 2008 Apr; 40(2):109-12. PubMed ID: 18560030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials for pediatric scleroderma.
    Rosenkranz ME; Lehman TJ
    Curr Rheumatol Rep; 2002 Dec; 4(6):449-51. PubMed ID: 12427357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scleroderma therapy: clinical overview of current trends and future perspective.
    Topal AA; Dhurat RS
    Rheumatol Int; 2013 Jan; 33(1):1-18. PubMed ID: 23011088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Juvenile scleroderma.
    Athreya BH
    Curr Opin Rheumatol; 2002 Sep; 14(5):553-61. PubMed ID: 12192254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients.
    Bellan M; Parisi S; Stobbione P; Pedrinelli AR; Rizzi E; Casciaro GF; Vassia V; Landi R; Cittone MG; Rigamonti C; Patrucco F; Ditto MC; Finucci A; Realmuto C; Todoerti M; Parodi M; Rossi P; Pirisi M; Fusaro E; Sainaghi PP
    Scand J Rheumatol; 2020 Nov; 49(6):505-506. PubMed ID: 32856492
    [No Abstract]   [Full Text] [Related]  

  • 7. Innovative therapies for systemic sclerosis.
    Ong VH; Denton CP
    Curr Opin Rheumatol; 2010 May; 22(3):264-72. PubMed ID: 20190640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis.
    Lin AT; Clements PJ; Furst DE
    Rheum Dis Clin North Am; 2003 May; 29(2):409-26. PubMed ID: 12841302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Considerations of Lung Involvement in Rheumatologic Disease.
    Robles-Perez A; Molina-Molina M
    Respiration; 2015; 90(4):265-74. PubMed ID: 26461464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic sclerosis: hypothesis-driven treatment strategies.
    Charles C; Clements P; Furst DE
    Lancet; 2006 May; 367(9523):1683-91. PubMed ID: 16714190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of systemic sclerosis.
    Steen VD
    Am J Clin Dermatol; 2001; 2(5):315-25. PubMed ID: 11721650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive systemic sclerosis.
    Medsger TA
    Clin Rheum Dis; 1983 Dec; 9(3):655-70. PubMed ID: 6360519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials for the treatment of systemic sclerosis/scleroderma.
    Varga J; Ponor I
    Curr Rheumatol Rep; 1999 Oct; 1(1):13-4. PubMed ID: 11123008
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic sclerosis (scleroderma). Clinical management of its major complications.
    Legerton CW; Smith EA; Silver RM
    Rheum Dis Clin North Am; 1995 Feb; 21(1):203-16. PubMed ID: 7732169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide therapy for scleroderma.
    Akesson A
    Curr Opin Rheumatol; 1998 Nov; 10(6):579-83. PubMed ID: 9812219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-modifying drugs for systemic sclerosis: why have we not found them yet?
    Derk CT
    Expert Rev Clin Immunol; 2011 Jul; 7(4):399-401. PubMed ID: 21790280
    [No Abstract]   [Full Text] [Related]  

  • 17. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.
    Tzelepis GE; Plastiras SC; Karadimitrakis SP; Vlachoyiannopoulos PG
    Clin Exp Rheumatol; 2007; 25(5):734-9. PubMed ID: 18078622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
    White B; Bauer EA; Goldsmith LA; Hochberg MC; Katz LM; Korn JH; Lachenbruch PA; LeRoy EC; Mitrane MP; Paulus HE
    Arthritis Rheum; 1995 Mar; 38(3):351-60. PubMed ID: 7880189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease modification and other trials in systemic sclerosis have come a long way, but have to go further.
    Pope JE; Khanna D; Johnson SR; Clements P
    Arthritis Care Res (Hoboken); 2012 Jul; 64(7):955-9. PubMed ID: 22422634
    [No Abstract]   [Full Text] [Related]  

  • 20. Thymoglobulin and cyclophosphamide as treatment for diffuse cutaneous systemic sclerosis.
    Holmberg LA; Furst DE; McSweeney PA; Nash RA
    J Rheumatol; 2009 Aug; 36(8):1839. PubMed ID: 19671826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.